The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis (NCT05356793) | Clinical Trial Compass
CompletedPhase 2
The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis
United States30 participantsStarted 2021-03-01
Plain-language summary
The objective of this study is to evaluate the efficacy of Sasch1, a novel anti-infective eyedrop, in the treatment of acute infectious conjunctivitis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Conjunctivitis (as defined below) within 72 hours of initial ocular symptoms.
* At least 18 years of age.
* Subjects capable of understanding the purpose and risks of the study, and able to give informed consent.
* Conjunctivitis diagnosis defined as presence of the two cardinal signs of acute conjunctivitis- 1) bulbar conjunctival injection and 2) conjunctival discharge/exudates.
* A three-point rating scale (0=absent, 1=mild, 2=moderate, 3=severe) will be employed to grade conjunctival discharge/exudates.
* All patients will require a rating of 1(mild) or greater for conjunctival discharge/exudates.
* Patients will require a rating of 1 (mild) for bulbar conjunctival injection.
Exclusion Criteria:
* Conjunctivitis greater than 72 hours after initial ocular symptoms
* Corneal ulcer, endophthalmitis, or any other confounding infection of the eye
* Patients taking topical anti-inflammatory medications on a chronic basis
* Known steroid glaucoma responders
* Active herpes ocular infection
* Pregnant women
* Known allergy to chlorhexidine